Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian CancerSetsuko K. Chambers, David S. Alberts, Alan N. Gordon et al.|Clinical Cancer Research|2010Cited by 55
Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian CancerSetsuko K. Chambers, David S. Alberts, H.‐H. Sherry Chow et al.|Clinical Cancer Research|2012Cited by 32
Evaluation of a Hypoxia Regulated Gene Panel in Ovarian CancerAmanda F. Baker, Setsuko K. Chambers, Scott W. Malm et al.|Cancer Microenvironment|2015Cited by 12
An unusual BRCA mutation distribution in a high risk cancer genetics clinicAnna C. Nelson-Moseke, Christina M. Laukaitis, Joanne Jeter et al.|Familial Cancer|2012Cited by 11
Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancerAmanda F. Baker, Setsuko K. Chambers, Denise J. Roe et al.|Investigational New Drugs|2012Cited by 0